Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 99. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply1776
Environment and infectious diseases1312
A step forward in the journey towards hookworm vaccines939
Surge of cutaneous leishmaniasis in Pakistan687
Is ceftriaxone similarly effective to benzylpenicillin in neurosyphilis? – Authors' reply642
Research in brief606
Research in brief600
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting499
Attention to skin-related neglected tropical diseases417
Infectious disease surveillance update382
Chronicling PEPFAR's work in Africa358
Ordinary people in extraordinary times311
Infectious disease surveillance update289
Promoting diversity and equity in publishing287
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7283
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study278
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges263
Adaora “Ada” Alise Adimora261
The superiority of bivalent over monovalent booster vaccines252
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum247
DNDi receives Dutch funding boost244
COVID-19 vaccination protects children and adolescents241
Reflecting on lessons from the 2014–16 Ebola virus outbreak237
Bold measures to accelerate malaria elimination229
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis229
A patient with secondary syphilis following incomplete treatment of primary infection224
Threat of HIV and tuberculosis drug resistance after US funding cuts220
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial217
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial212
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco210
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations208
HIV vaccine trial failure205
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial193
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom191
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study187
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic186
Updated criteria for paediatric sepsis and septic shock180
The next chapter for Africa's genomic initiatives178
Transitioning to endemicity with COVID-19 research172
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children 172
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation172
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden169
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines167
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C167
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria166
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study166
Measles immunity gaps and outbreak risk in a shifting landscape165
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect160
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review158
The importance of understanding the infectious microenvironment157
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin157
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study156
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study153
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis153
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial152
Listeria monocytogenes: a rare, deadly cause of peritonitis152
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations151
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1146
Mpox in people with past infection or a complete vaccination course: a global case series143
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2142
History and evolution of tuberculosis and global health141
Supporting healthcare access for refugees and migrants141
Assessment of experimental malaria vaccine induced protection in pre-exposed populations140
Election of Regional Director for the Western Pacific136
The implications of mpox breakthrough infections on future vaccination strategies135
Severe influenza: is there a role for antiviral combinations?134
Sizing the reservoirs of malaria transmission: the contribution of school-aged children133
Correction to Lancet Infect Dis 2021; 21: 962–74131
Emil Gotschlich129
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world129
Interplay of infection and vaccination in long-term protection from COVID-19127
Immune evasiveness of SARS-CoV-2 variants and vaccine selection126
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis124
Global cholera resurgence—a preventable tragedy124
Super-spreaders: a historical review123
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis122
Elisabeth Presterl—always looking forward120
WHO Pathogen X conference120
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant119
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?119
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents118
What can be learnt from the world's first national vaccination programme against gonorrhoea117
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study117
Research in brief116
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study112
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis111
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape110
The global burden of cryptococcosis—a neglected tropical disease?109
Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study107
Addressing the shortage of cholera vaccines105
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms104
Malaria vaccine development in Mali: a step towards transmission-blocking strategies104
Correction to Lancet Infect Dis 2023; 23: e469103
Research in brief102
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0102
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5102
Full-dose NSAIDs at the first sign of respiratory infection?101
Theresa Ochoa—staying on top of infectious diseases in Peru99
Infectious disease surveillance update99
0.096878051757812